Business
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
(via TheNewswire) LONDON, ONTARIO / TheNewswire / January 28, 2019 - Sern...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019(via TheNewswire)\n \n \nLONDON, ONTARIO / TheNewswire / January 28, 2019 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV -- Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday January 28th at 11:00 a.m. Eastern Time. \n\n \n \nThe panel will cover a broad spectrum of interests involving diabetes including the discovery and commercialization of novel diabetes therapeutics and diagnostics, diabetes research, as well as nutrition and awareness. Included on the panel are Dr. Camillo Ricordi, Director of the Diabetes Research Institute; Dr. Michael Castagna, CEO of MannKind Corporation; Steve Perrin, Ph.D., CEO and Founder of Anelixis Therapeutics; William L. Rust, Ph.D., CEO and Founder of Seraxis; Michael Fox of DugalHealth; Martin Beland, VP Marketing and Strategic Development of Inolife Sciences; Steve Glover, CEO of Variant Pharmaceuticals; and Dr. Philip Toleikis, Ph.D., President & CEO of Sernova Corp.\n\n \n \nA video webcast of the presentation will be available the following day on the company's website www.sernova.com and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (http://nobleconference.com) as well as on the new investor portal created by Noble called Channelchek (http://www.channelchek.com).\n\n \n \nAbout Sernova, Corp\nSernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova's primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such a...